GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,707.40p
   
  • Change Today:
      2.20p
  • 52 Week High: 1,711.20
  • 52 Week Low: 1,316.00
  • Currency: UK Pounds
  • Shares Issued: 4,144.88m
  • Volume: 387,685
  • Market Cap: £70,770m
  • RiskGrade: 129

GSK abandons regulatory submissions of rheumatoid arthritis drug

By Iain Gilbert

Date: Thursday 27 Oct 2022

LONDON (ShareCast) - (Sharecast News) - Drugmaker GSK revealed on Thursday that it will not proceed with regulatory submissions of its experimental treatment for moderate-to-severe rheumatoid arthritis after the drug candidate failed to meet a key endpoint in a recent study.
GSK said that a late-stage study on otilimab, its antibody-based drug, showed it failed to make a meaningful difference in improving swelling and tenderness in joints to aid movement in patients who had not previously responded to other forms of treatment.

"The limited efficacy demonstrated does not support a suitable benefit/risk profile for otilimab as a potential treatment for RA," said GSK.

The FTSE 100-listed group also said it has come closer to locking in its first new drug approval since its consumer health spin-off back in July, with an expert panel of the Food and Drug Administration backing the approval for daprodustat - its drug aimed at treating anemia in certain patients with chronic kidney disease.

GSK's senior vice president of development Chris Corsico said: "Today's robust discussion was an important step in the review of daprodustat. We are pleased the committee recognised the potential for daprodustat to help certain patients who are living with anaemia of CKD given limited treatment options.

"We want to thank the physicians, patients, and advocacy community who shared their valuable insights about this disease. We look forward to continuing to work with the US FDA as they complete their review of our new drug application."

As of 0830 BST, GSK shares were down 0.30% at 1,390.80p.





Reporting by Iain Gilbert at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,707.40p
Change Today 2.20p
% Change 0.13 %
52 Week High 1,711.20
52 Week Low 1,316.00
Volume 387,685
Shares Issued 4,144.88m
Market Cap £70,770m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
83.02% below the market average83.02% below the market average83.02% below the market average83.02% below the market average83.02% below the market average
51.85% below the sector average51.85% below the sector average51.85% below the sector average51.85% below the sector average51.85% below the sector average
Price Trend
49.26% above the market average49.26% above the market average49.26% above the market average49.26% above the market average49.26% above the market average
75.44% above the sector average75.44% above the sector average75.44% above the sector average75.44% above the sector average75.44% above the sector average
Income
35.10% above the market average35.10% above the market average35.10% above the market average35.10% above the market average35.10% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average
Growth
27.09% below the market average27.09% below the market average27.09% below the market average27.09% below the market average27.09% below the market average
29.73% above the sector average29.73% above the sector average29.73% above the sector average29.73% above the sector average29.73% above the sector average

What The Brokers Say

Strong Buy 7
Buy 6
Neutral 9
Sell 2
Strong Sell 0
Total 24
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q4 Q3
Ex-Div 22-Feb-24 16-Nov-23
Paid 11-Apr-24 11-Jan-24
Amount 16.00p 14.00p

Trades for 28-Mar-2024

Time Volume / Share Price
09:32 339 @ 1,707.40p
09:32 185 @ 1,707.40p
09:32 156 @ 1,707.40p
09:32 152 @ 1,707.40p
09:32 194 @ 1,707.40p

GSK Key Personnel

CEO Emma Walmsley

Top of Page